Provided by Tiger Trade Technology Pte. Ltd.

TELA Bio, Inc.

0.6229
-0.0234-3.62%
Volume:32.65K
Turnover:21.02K
Market Cap:27.88M
PE:-0.80
High:0.6561
Open:0.6561
Low:0.6229
Close:0.6463
52wk High:2.00
52wk Low:0.5011
Shares:44.77M
Float Shares:21.52M
Volume Ratio:0.58
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7776
EPS(LYR):-0.8300
ROE:-616.62%
ROA:-33.40%
PB:-1.76
PE(LYR):-0.75

Loading ...

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 08

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Irhythm Technologies (IRTC) and TELA Bio (TELA)

TIPRANKS
·
May 01

TELA Bio Reshapes Board, Appoints New Chairman, Directors

TIPRANKS
·
May 01

TELA Bio sees Q1 revenue about $19 million, above prior $18.5 million view

Reuters
·
May 01

TELA Bio names Joseph Capper board chair in four-director refreshment plan

Reuters
·
May 01

TELA Bio Inc - Prelim Q1 2026 Revenue Approx $19.0 Mln Versus Guidance of $18.5 Mln

THOMSON REUTERS
·
May 01

TELA Bio Inc - Joseph Capper to Be Nominated as Director and Expected to Serve as Chair

THOMSON REUTERS
·
May 01

TELA Bio Inc - Chairman Doug Evans, Kurt Azarbarzin, Vince Burgess, Federica O’brien to Depart Board

THOMSON REUTERS
·
May 01

Press Release: TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues

Dow Jones
·
May 01

TELA Bio (TELA) Gets a Buy from Canaccord Genuity

TIPRANKS
·
Apr 24

TELA Bio to Announce First Quarter 2026 Financial Results

GlobeNewswire
·
Apr 22

TELA Bio Is Maintained at Market Outperform by Citizens

Dow Jones
·
Mar 27

Tela Bio price target lowered to $3 from $5 at Citizens

TIPRANKS
·
Mar 27

TELA Bio Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Mar 25

Tela Bio price target lowered to $2 from $4 at Canaccord

TIPRANKS
·
Mar 25

TELA Bio Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 25

TELA Bio: Expects Full Year 2026 REV Growth of at Least 8% Over Full Year 2025

THOMSON REUTERS
·
Mar 25

TELA Bio: Expects Q1 2026 Revenue of About $18.5 Mln

THOMSON REUTERS
·
Mar 25

TELA Bio Q4 revenue rises 18% to USD 20.9 million as operating loss narrows 20.6% to USD 6.6 million

Reuters
·
Mar 25

TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire
·
Mar 25